ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 1004 • ACR Convergence 2024

    Predictors of Post-acute Sequelae of COVID-19 in Patients with Rheumatoid Arthritis: A Retrospective Analysis of a Large Health System in the Midwestern United States

    Ernesto Lopez Castillo1 and Jeffrey Ording2, 1University of Colorado, Denver, CO, 2Advocate Illinois Masonic Medical Center, Chicago, IL

    Background/Purpose: Evidence suggests that patients with autoimmune diseases or immunosuppressive conditions have a higher risk of poor outcomes related to Coronavirus disease 2019 (COVID-19) infection.…
  • Abstract Number: 1047 • ACR Convergence 2024

    Impact of Treatment Switching on Adherence in Members with Rheumatoid Arthritis, Psoriatic Arthritis, or Systemic Lupus Erythematosus

    Jean Park1, Cliff Rutter2, Elisea Avalos-Reyes3, Mary Anderson4, Will Cavers5, Dorothea Verbrugge6 and Kjel Johnson7, 1CVS Health, Hartford, CT, 2CVS Health, Fair Oaks Ranch, TX, 3CVS Health, Highland Village, TX, 4CVS Health, Irving, TX, 5CVS Health, Palm Beach Gardens, 6CVS Health, Salt Lake City, 7CVS Health, Tampa

    Background/Purpose: Switching treatment from conventional to biologic disease-modifying antirheumatic drugs (DMARDs) is a common practice for managing autoimmune diseases such as rheumatoid arthritis (RA), psoriatic…
  • Abstract Number: 1316 • ACR Convergence 2024

    Dual Therapy with a JAKi and bDMARD in Patients with Standard Treatment Resistant Rheumatic Disease: A Case Series

    Bella Garg1, John Antowan2 and daniel Furst3, 1Centinela Hospital Medical Center, Inglewood, CA, 2UCLA, Los Angeles, 3Pacific Arthritis Center, Inglewood

    Background/Purpose: Due to concerns about side effects, combined JAK inhibitors (JAKi) and biologic DMARDs (bDMARDs) have not been recommended for rheumatologic conditions. However, combining them…
  • Abstract Number: 1340 • ACR Convergence 2024

    Characteristics and Long-term Outcomes of Patients with Rheumatoid Arthritis and Concurrent Calcium Pyrophosphate Deposition Disease

    Natalie Schanzer1, Ted Mikuls2, Bryant England2, Katherine Wysham3, Jorge Rojas4, Sauer brian5, Beth Wallace6, Rachel Elam7, Andreas Reimold8, Gail Kerr9, John Richards10, Gary Kunkel11, Iris Lee12, Isaac Smith13, Paul Monach14, grant Cannon15 and Joshua Baker16, 1Perelman School of Medicine at University of Pennsylvania, Philadelphia, PA, 2University of Nebraska Medical Center, Omaha, NE, 3VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, 4Seattle VA, Mexico, Mexico, 5Salt Lake City VA/University of Utah, Salt Lake City, UT, 6Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, 7Augusta University, Evans, GA, 8Dallas VA Medical Center, Dallas, TX, 9Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 10Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, 11University of Utah and George E Wahlen VAMC, Salt Lake City, UT, 12Washington University in St Louis, Saint Louis, MO, 13Duke University Hospital, Durham, NC, 14VA Boston Healthcare System, Boston, MA, 15University of Utah and Salt Lake City VA, Salt Lake City, UT, 16University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Calcium pyrophosphate deposition disease (CPPD) is a common crystalline arthritis that can both present alongside rheumatoid arthritis (RA) and, given its similar pattern of…
  • Abstract Number: 1356 • ACR Convergence 2024

    Association Between Vascular Inflammation and Kidney Function in Patients with Rheumatoid Arthritis: Secondary Analysis of TARGET Trial

    Sho Fukui1, Ahmed Tawakol2, Wolfgang Winkelmayer3, Leah Santacroce4, Jon Giles5, Katherine Liao4, Joan Bathon6 and Daniel Solomon7, 1Brigham and Women's Hospital, Brookline, MA, 2Massachusetts General Hospital/Harvard Medical School, Boston, MA, 3Baylor College of Medicine, Houston, 4Brigham and Women's Hospital, Boston, MA, 5Cedars Sinai Medical Center, Los Angeles, CA, 6Columbia University, NEW YORK, NY, 7Brigham and Women's Hospital, Newton, MA

    Background/Purpose: Kidney dysfunction is a common complication in patients with rheumatoid arthritis (RA). More severe disease activity is associated with a larger decline in the…
  • Abstract Number: 1372 • ACR Convergence 2024

    Upadacitinib and Other JAK Inhibitors in the Treatment of Rheumatoid Arthritis – Interstitial Lung Disease. National Multicenter Study Clinical Practice.

    Ana Serrano-Combarro1, Belén Atienza-Mateo2, Jesús Loarce3, Leticia del Olmo Perez4, Sara García-Pérez5, Guillermo Gonzalez Mozo de Rosales6, José Rosas-Gómez de Salazar7, Ana Urruticoechea-Arana8, Andrea García-Valle9, Juan Moreno Morales10, María Martín López11, Patricia Lopez Viejo12, Virginia Ruiz-Esquide13, Julia Fernandez Melon14, David Castro-Corredor15, Ana Fernández-Ortiz16, Rafael Benito Melero-Gonzalez17, Carolina Díez Morrondo18, Desiree Palma19, Natividad del Val del Amo20, Natalia Mena Vázquez21, Alicia García Dorta22, MARÍA JOSÉ PÉREZ GALÁN23, MARINA SOLEDAD MORENO GARCIA24 and Ricardo Blanco-Alonso25, and on behalf of JAKi in Interstitial Lung Disease Associated with Rheumatoid Arthritis, 1Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, 2Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, 3Ramón y Cajal University Hospital, Madrid, Madrid, Spain, 4HOSPITAL NUESTRA SEÑORA DEL PRADO, TALAVERA DE LA REINA, Spain, 5Complejo Hospitalario de Vigo, Vigo, Galicia, Spain, 6Basurto University Hospital, Bilbao, Spain, 7Hospital Marina Baixa, PALMA DE MALLORCA, Comunidad Valenciana, Spain, 8Hospital Son Espases, Palma de Mallorca, Islas Baleares, Spain, 9Hospital General Río Carrión, Palencia, Spain, 10Hospital Universitario Santa Lucia Cartagena, Murcia, Murcia, Spain, 11General University Hospital of Ciudad Real, Ciudad de México, Spain, 12Hospital Severo Ochoa, Madrid, Madrid, Spain, 13Hospital Clinic de Barcelona, Barcelona, Spain, 14Hospital Son Espases, Palma, Spain, 15General University Hospital of Ciudad Real, Santa Cruz de Mudela (Ciudad Real), Spain, 16Hospital Universitario de Badajoz, Badajoz, Spain, 17CHU Ourense, O Carballino, Spain, 18Complejo Asistencial Universitario de Leon, Leon, 19Hospital Rafael Méndez, Lorca, Murcia, Spain, 20Complejo Hospitalario de Navarra, Pamplona, Spain, 21IBIMA, Málaga, Andalucia, Spain, 22Rheumatologist, La Laguna, Spain, 23SERVICIO ANDALUZ DE SALUD, GRANADA, Andalucia, Spain, 24Hospital Universitario Miguel Servet, GIJON, Asturias, Spain, 25Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

    Background/Purpose: Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Abatacept and rituximab are the recommended drugs. JAK inhibitors (JAKi) have…
  • Abstract Number: 1389 • ACR Convergence 2024

    Cohort Study on Drug Survival and Tolerability of Adalimumab Biosimilar Transitioning: Pharmaceutical Properties Do Matter

    Amy Peeters1, Maike Wientjes2, Wieland Müskens1, David Ten Cate3, Bart van den Bemt4, Noortje van Herwaarden1 and Alfons den Broeder2, 1Sint maartenskliniek, Nijmegen, Netherlands, 2Sint Maartenskliniek, Ubbergen, Netherlands, 3Sint Maartenskliniek, Rotterdam, Netherlands, 4Sint Maartenskliniek / Radboudumc, Ubbergen, Netherlands

    Background/Purpose: Since the compound patent on the bio-originator of adalimumab expired, several adalimumab biosimilars (BS) have been introduced. Extensive research shows equivalence in effectiveness and…
  • Abstract Number: 1647 • ACR Convergence 2024

    Improved Fertility in Women with Rheumatoid Arthritis and a Wish to Conceive When Treated According to a Treat-to-target Approach Aimed at Remission

    Cornelia H. Quaack1, Esther Röder1, Hetty M. Wintjes1, Anneke J. van Steensel-Boon1, Annemarie G.M.G.J. Mulders2, Laura C.J. Kranenburg-van Koppen1 and radboud J.e.m. Dolhain1, 1Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, 2Department of Obstetrics and Gynaecology, Erasmus Medical Center, Rotterdam, Netherlands

    Background/Purpose: Time to conception, known as time to pregnancy (TTP), is prolonged in women diagnosed with RA. High rates of infertility, defined as the inability…
  • Abstract Number: 1714 • ACR Convergence 2024

    Avoidable Hospitalizations by Persons with Rheumatoid Arthritis: A Population-Based Study Using Administrative Data

    Dani Contreras1, Claire Barber1, J. Antonio Avina-Zubieta2, Hude Quan1, Seungwon Lee1, James King1 and Cheryl Barnabe1, 1University of Calgary, Calgary, AB, Canada, 2Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada

    Background/Purpose: Ambulatory care sensitive conditions (ACSCs) are conditions where appropriate access to ambulatory care can reduce hospitalizations. People with rheumatoid arthritis (RA) are at higher…
  • Abstract Number: 1849 • ACR Convergence 2024

    Selective Targeting of One-Carbon Metabolism to Combat Rheumatoid Arthritis

    Theodora Manolakou1, Sanjaykumar Boddul1, George Sentis2, Michail Angelos Panagias1, Martina Samiotaki3, Dionysis Nikolopoulos1, Ana Slipicevic1, Kumar Sanjiv1, Martin Henriksson1, Oliver Mortusewicz1, Aikaterini Chatzidionysiou1, Per-Johan Jakobsson1 and Thomas Helleday1, 1Karolinska Institutet, Stockholm, Sweden, 2Biomedical Reseearch Foundation Academy of Athens, Athens, Greece, 3Alexander Fleming Biomedical Sciences Research Center, Athens, Greece

    Background/Purpose: Rapidly proliferating cells fuel their increased nucleotide demand by boosting one-carbon metabolism, associated with the survival of pathogenic proliferative cells and the release of…
  • Abstract Number: 1915 • ACR Convergence 2024

    Patient-reported Difficulties Regarding Reproductive Health Discussions in an Urban Outpatient Setting

    Martha Delgado1, Cassidy Hernandez-Tamayo2, Melissa Wilson2 and Leanna Wise3, 1Los Angeles General Hospital/Keck Medicine of USC, Costa Mesa, CA, 2Keck School of Medicine of USC, Los Angeles, CA, 3LAGMC/Keck Medicine of USC, Los Angeles, CA

    Background/Purpose: Timely reproductive health conversations in the rheumatology outpatient setting are essential for optimal maternal-fetal health; however, the literature suggests that these conversations happen for…
  • Abstract Number: 2130 • ACR Convergence 2024

    Post-fracture Survival for Rheumatoid Arthritis Patients Is Not Improving

    Owen Taylor-Williams1, Johannes Nossent2 and Charles Inderjeeth3, 1University of Western Australia, Perth, Western Australia, Australia, 2University of Western Australia, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia, 3SCGH and OPH Group & University of Western Australia, Perth, Western Australia, Australia

    Background/Purpose: Improved disease control for articular manifestations of Rheumatoid arthritis (RA), has resulted in more attention being directed to extra-articular (ExRA) manifestations (cardiovascular events, osteoporosis,…
  • Abstract Number: 2219 • ACR Convergence 2024

    Association of Chondrocalcinosis with Disease Activity and Drug Response in Rheumatoid Arthritis: Baseline Characteristics of the Swiss Rheumatoid Arthritis Outcomes Cohort

    Tobias Manigold1, Nicolas Bodmer2, Rosoux Elisabeth3, Deborah Markham4, Guillaume Fahrni3, Raphael Micheroli5, Lucas Bachmann2, Jonas Brändli6, Fabio Becce7 and Thomas Hügle8, 1Department of Rheumatology, Inselspital University Hospital Bern, Bern, Switzerland., Bern, Switzerland, 2Medignition, Zürich, Switzerland, 33) Department of Radiology, Lausanne University Hospital (CHUV), University of Lausanne (UNIL), Lausanne, Switzerland, Lausanne, Switzerland, 4Department of Rheumatology, University Hospital Lausanne (CHUV), Switzerland, Lausanne, Switzerland, 5University Hospital Zurich, Zurich, Switzerland, 66) Data Science Team, Swiss Clinical Quality Management Foundation, Zurich, Switzerland, Zürich, Switzerland, 7Lausanne University Hospital (CHUV), Lausanne, Switzerland, 8Lausanne University Hospital, Lausanne, Switzerland

    Background/Purpose: Calcium pyrophosphate deposition disease (CPPD) disease can mimic or interfere with the course of rheumatoid arthritis (RA). Previous studies suggest higher prevalence of Chondrocalcinosis…
  • Abstract Number: 2236 • ACR Convergence 2024

    Relation Between Sociodemographic Factors and Hand Function in Patients with Early Rheumatoid Arthritis

    Maria Rydholm1, Mohaned Hameed2, Anna Eberhard2, Ankita Sharma2, Giovanni Cagnotto2 and Carl Turesson2, 1Skåne University Hospital, Malmö, Sweden, 2Lund University, Malmö, Sweden

    Background/Purpose: Rheumatoid arthritis (RA) is characterized by polyarticular involvement of the hands, leading to impaired function. The impact of active inflammation on disability in early…
  • Abstract Number: 2255 • ACR Convergence 2024

    Differences in Pharmacological Prescription to Patients with Recent-onset Arthritis: Analysis from the Gender Perspective

    Maryia Nikitsina, María Ahijón Lana and Isidoro González-Álvaro, University Hospital La Princesa, Madrid, Madrid, Spain

    Background/Purpose: Nowadays the honing in on sex-specific treatment options is the most productive way to move forward with the larger effort of implementing precision medicine.…
  • « Previous Page
  • 1
  • …
  • 15
  • 16
  • 17
  • 18
  • 19
  • …
  • 188
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology